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Type 2 Myocardial Infarction – the Chimaera of cardiology? 
The Chimera (Χίµαιρα, Chímaira) was a monstrous fire-breathing hybrid creature of Lycia 
in Asia Minor, composed of the parts of more than one animal. Usually depicted as a lion, 
with the head of a goat arising from its back, and a tail that might end with a snake's head. 
The term chimera has come to describe any mythical or fictional animal with parts taken 
from various animals, or to describe anything composed of very disparate parts, or perceived 
as wildly imaginative, implausible, or dazzling. Is Type 2 myocardial infarction the chimaera 
of cardiology? 
It is worth reviewing how “type 2 myocardial infarction” evolved. The development of the 
concept of type 2 myocardial infarction parallels the evolution of cardiac troponin assays. 
The initial generation of cardiac troponin assays were relatively insensitive[1 2 3]. They were 
superior to the existing conventional “cardiac enzyme” measurements at detecting 
prognostically significant myocardial injury in patients with an underlying pathophysiology 
of acute plaque rupture[4 5]. It was this property, combined with absolute cardiospecificity 
that led to their initial adoption. At this point, decision limits were chosen to confer 
specificity on the assay and were optimised for equivalence with myocardial infarction as 
defined by existing WHO criteria[6 7]. The background level of cardiac troponin detectable 
in the normal healthy individual was considered to be zero. A reference interval did not exist, 
only a single decision threshold[6 7 8].  
 
Cardiac troponin measurement offered the Emergency Department physician and, to a lesser 
extent the cardiologist, a dream test[9]. The presence or absence of detectable cardiac 
troponin said whether the patient had suffered a myocardial infarction or not. However, early 
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on it was found that many patients classified as unstable angina according to contemporary 
criteria had detectable troponin levels, although below the decision limit for myocardial 
infarction[4 6 10 11]. These patients had a similar prognosis to those diagnosed with 
myocardial infarction. A special term was suggested for this finding, "minor myocardial 
damage”[6 12]. However, the term was never adopted by cardiological societies and the 
original redefinition of myocardial infarction considered the role of the new cardiac specific 
biomarker, cardiac troponin and defines myocardial infarction in terms of the decision limit 
for normality, the 99
th
 percentile[13]. It also recommends an analytical imprecision goal of < 
10%. Hence, all reliably detected troponin elevations in a clinical context of an acute 
coronary syndrome were considered indicative of an acute myocardial infarction. Notably, in 
the original redefinition of myocardial infarction there is no such thing as type 2 myocardial 
infarction. 
 
At that time the majority of cardiac troponin methods were unable to define a true 99
th
 
percentile. The limit of detection of the assay was a long way above the 99
th
 percentile as was 
the 10% CV[14]. The redefinition of myocardial infarction acted as a spur to the 
manufacturers. Progressive improvements in assay technology reduced the limit of detection 
of cardiac troponin measurements and improved assay (im)precision. In addition, there was 
widespread measurement of cardiac troponin in patients other than those with acute chest 
pain. A growing number of studies confirmed early reports[15 16] that troponin was 
measureable and often a prognostic marker outside of the chest pain population[17 18]. In 
parallel with this, the increasingly widespread use of coronary angiography led to the 
realization that many patients with troponin elevation do not have evidence of plaque rupture 
or erosion of the intima with overlying thrombus formation in the coronary vessel or not even 
angiographically detectable atherosclerosis at all[19 20]. It is in this context that the concept 
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of a different sort of ischaemia producing another type of myocardial infarction was 
suggested. 
Type 1 MI has always been clearly understood as troponin elevation in the context of acute 
plaque rupture and the clinical scenario of a suspected acute coronary syndrome[21 22]. The 
pathophysiology of type 1 myocardial infarction is well-defined. The relationship between 
troponin elevation, histopathological findings and cardiac imaging is well understood[23 24 
25]. The treatment strategies are well-defined and based on prospective randomised 
controlled trials[26]. The combination of cardiac troponin measurement and intervention with 
improved outcomes is one of the triumphs of modern cardiology. The advent of more 
sensitive troponin measurements has simply allowed earlier diagnosis and intervention[27 28 
29] with only a small increase in the absolute numbers of type I MI[30]. In contrast, type 2 
myocardial infarction has always been defined by what it is not rather than what it is. The 
definition of type 2 myocardial infarction is[21] 
“myocardial infarction secondary to ischaemia due to either increased oxygen demand or 
decreased supply, e.g. coronary artery spasm, coronary embolism, anaemia, arrhythmias, 
hypertension or hypotension.” 
Troponin elevation occurs in a large number of clinical situations not considered to be an 
acute myocardial infarction[21 31]. The troponin elevation is associated with severity of 
illness and an adverse prognosis in the condition described[31 32 33]. Type 2 MI has been 
used to describe a subset of these conditions where myocardial ischaemia and cardiac 
myocyte damage is considered to be the representative pathology in an overlap with classical 
(type 1) myocardial infarction. Does current evidence support this approach? 
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The definition of type 1 MI includes a troponin above the 99
th
 percentile and a significant 
change in troponin value, the delta troponin. It would seem attractive to use delta troponin to 
distinguish between type 1 and type 2 MI. It is our experience and the experience of 
others[33 34] that although delta troponin can be used to distinguish between acute and 
chronic myocardial injury from any cause, it cannot be used to distinguish between type 1 
and type 2 MI. To date there have been no histopathological studies that have examined the 
pattern of tissue injury in type 2 myocardial infarction or a good animal model of 
pathophysiology. That myocardial injury occurs is not in doubt but the mechanism by which 
it occurs remains speculative. Therefore, there is considerable disagreement among 
researchers and clinicians how type 2 myocardial infarction should be defined[35 36]; and 
even worse how type 2 myocardial infarction should be diagnosed in clinical practice[37]. 
This uncertainty is reflected in the current clinical literature that has examined type 2 
myocardial infarction (table 1). The populations examined have varied from clinical trial 
populations with suspected acute coronary syndrome [38] to more clinically representative 
patients presenting with chest pain[34 39 39]. Studies have included multicentre randomised 
controlled trials of therapeutic agents [38], single centre [34 36] or multicentre prospective 
observational studies[35 39 40], retrospective case record reviews [41] and registry 
studies[37 42]. The incidence of type 2 myocardial infarction has varied significantly across 
the studies from 1.6% [41]to 29.6%[36]. The criteria used are similarly disparate although all 
studies claim to use the universal definition. There are a range of different conditions 
associated with a diagnosis of type 2 MI (Table 2)[35 37 42] including some well described 
associations such as heart failure[43]. This, in itself, reflects the inherent confusion in the 
term type 2 MI. Type 2 MI is described in different series as being associated with [35 40], 
caused by [42] or with a secondary diagnosis considered to be the trigger of the type 2 M 
I[37]. In reality, the diagnosis of type 2 MI as defined by troponin elevation can only be 
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associated with another clinical condition as a pathophysiology is not defined. In two studies 
in the literature evidence of significant coronary artery disease has been required for making 
the diagnosis of type 2 myocardial infarction[36 44], although that is not an obligatory part of 
the definition that was proposed in the Universal definition of myocardial infarction[21 31]. 
There has been no study to date where all patients had their coronary anatomy defined prior 
to classification into type 1 or type 2 MI. Hence, type 2 myocardial infarction as defined 
according to the Universal definition [21](and third Universal definition)[22] of myocardial 
infarction is a mixed bag of patients, in whom the pathophysiology is different and, in fact in 
many cases, is unknown. 
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Table 1  Type 2 myocardial infarction in different studies – populations, incidence and outcomes 
 
Reference Population Criteria n  MI Type 1 
MI 
Type 2 MI Troponin assay Mortality 
compared with 
no MI 
Mortality type 1 vs 
type 2 
Mortality  
predictors 
Morrow, 
Bonaca 
[38 45] 
 
Prospective trial 
patients with ACS 
undergoing PCI 
randomized to 
clopidogrel or  
prasugrel 
Adjudicated end 
point committee 
using the universal 
definition  
13608 1218 397 
(32.6%) 
43 (3.5%) 
778 
(63.9%) 
Type 3-5 
Local laboratory 
assay and 
decision limit 
180 days 
No MI 0.49% 
Type 2 MI 6.2% 
HR 5.4 (1.3-
22.9) 
180 days 
Unadjusted  
No MI 1.0% 
Type 1 6.4% HR 3.7 
(1.9-7.0) 
Type 2 7.4% HR 2.7 
(0.7-11.4). 
Adjusted 
Type 1 HR 4.1; 95% 
CI, 2.7– 6.3, P<0.001 
Type 2 HR 2.8; 95% 
CI, 
0.9–8.8; P = 0.085 
 
Javed 
[36] 
Prospective 
enrolment of 
consecutive 
admissions over a 
3 month period 
from the 
emergency 
department or 
inpatient beds and 
found to have an 
abnormal troponin 
2 Reviewers 
Clinical ischaemia 
documented, No 
angiographic lesion 
or documented 
supply/demand 
mismatch 
2942 216 143 
(66.2%) 
64(29.6%)
9 (4.1%) 
unclassifie
d (type 3 
and 4) 
Siemens ultra 
(contemporary 
sensitive) 99
th
 
percentile 40 ng/L 
No data In hospital mortality 
Type 1 11%, Type 2 
14% ns. 
Peak cTnI 
Hyperlipid
aemia 
Recreation
al drugs 
Angiogram 
result 
Melberg 
[41] 
Retrospective 
identification over 
1 year of patients 
with an ACS 
diagnosis, 
admissions with a 
troponin 
measurement, all 
patients admitted 
Adjudicated 
diagnosis (2 
reviewers plus 1 
adjudicator) 
Universal definition 
1093 1093 967 
(88.5%) 
17 (1.6%) 
109 (10%) 
Type 3-5 
Roche 4th 
generation 99th 
percentile 30 ng/L 
No data No data  
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for 
revascularization 
and all with 
sudden death?MI 
Saaby 
[35] 
Prospective 
enrolment over 1 
year of all patients 
who had cTnI 
measured 
3 adjudicators. 
Strict criteria for 
supply or demand 
mismatch. 
Angiographic 
classification not 
used. 
 
4499, 
1961 
with 
elevated 
cTnI 
(43.5%) 
553 397 
(71.7%) 
144 
(26.0%) 
12 (2.2%) 
Type 4-5 
 
Architect 
contemporary 
assay.  
Cut off 30 mg /L 
(10% CV 32 
ng/L, 99th 
percentile 28 
ng/L) 
   
Saaby 
[40] 
Prospective 
enrolment over 1 
year of all patients 
who had cTnI 
measured 
3 adjudicators. 
Strict criteria for 
supply or demand 
mismatch. 
Angiographic 
classification not 
used. 
 
3762, 
1577 
with 
elevate d 
cTnI 
(41.9%) 
488 360 
(73.7%) 
119 
(24.4%) 
9 (1.8%) 
Type 4/5 
Architect 
contemporary 
assay.  
Cut off 30 ng/L 
(10% CV 32 
ng/L, 99th 
percentile 28 
ng/L) 
No data Mortality type 1 vs 
type 2 
In hospital 6.9% vs 
19.3%  
30 day 9.2% vs 
23.6% 
1 year 16.7% vs 
43.7% 
P <0.0001 
Age 
Type 2 MI 
Smoking 
Hyperchol
esterolaem
ia 
Prior MI 
Ejection 
fraction 
Creatinine 
Sandoval 
[34] 
Prospective 
unselected 
consecutive ED 
admissions over 6 
months 
2 separate 
reviewers, 
consensus 
resolution of 
disagreement. 
Universal definition 
1144, 
32 ST 
elevation 
MI 
(exclude
d) 
856 no 
MI 
256 66 (6%) 190 (17%) Ortho diagnostics 
(contemporary 
sensitive) 10% 
CV 34 ng/L, 99th 
percentile 34 ng/L 
180 day 
No MI 3.2%, 
type 2 MI 
11.4% p<0.001 
180 day 
Type 1 7.6%, type 2 
11.4% ns 
 
 
 
 
 
 
 
Smith 
[39] 
Multicentre study 
of prospective ED 
admissions with 
?ACS over 9 
months 
Central 
adjudication(3 
reviewers) 
Universal definition  
1096 
962 no 
MI 
134 127 
(94.7%) 
7 (5.2%) 13 different 
assays, 99
th
 
percentile. 
No data No data  
Stein 
[42] 
Registry study of 
ACS patients 
CCU and 
Local clinician 
Universal definition 
 2818 2691 
(95.5%) 
127 (4.5%) Local assays No data In hospital type 1 
4.2% type 2  11.8% p 
= 0.0005 
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cardiology wards 
plus 37 Internal 
medicine wards 
30 day type 1 4.9% 
type 2 13.6% 
One year type 1 4.4% 
type 2 12.2% p 
<0.0001 
Baron[37] 
 
Registry study of 
consecutive 
admissions with 
MI  admitted to 
cardiac or medical 
intensive care 
Local clinician 
Universal definition 
 1976
3 
17488 
(88.5%) 
1403 
(7.1%) 
872 (4.4%) 
Type 3-5 
or 
unclassifie
d 
Local assays No data I year Unadjusted  
Type 1 13.5% type 2 
24.7% p <0.001(HR 
type 2 1.86 (1.66-
2.08) Adjusted 1.03 
(0.86-1.23) 
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Table 2  Conditions associated with Type 2 Myocardial infarction in different series. 
 Saaby[35] Stein[42] Baron[37] 
n 144 127 1403 
Anaemia 30 (20.8%) 39 (31%) 186 (13.3%) 
Shock 9 (6.2%) 18 (14%)  
Bradyarrthymia 4 (2.8%)  
22 (17%) 
 
VT 14 (9.7%) 
331 (23.6%) 
SVT 28(19.4%) 
Respiratory failure 30 (20.8%)  19 (1.4%) 
COPD/Asthma   78 (5.6%) 
Pulmonary oedema 13 (9.0%)   
Heart failure   260 (18.5%) 
Sepsis  30(24%) 246 (17.5%) 
Post-operative  18 (14%)  
Heart failure  14 (11%)  
Valve disease  13(10%)  
Stress  4(3%)  
Drugs  2(2%)  
Other  5(4%)  
Renal insufficiency   82 (5.8%) 
Hypertension/Hypertensive 
crisis 
1 (0.7%)  30 (2.4%) 
Stroke/TIA   24 (1.7%) 
Multifactorial 15 (10.4%)   
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In addition to type 2 MI troponin release occurs in a range of conditions where myocardial 
injury may be ischaemic or non-ischaemic or both[32 46]. This has been christened non-
ischaemic myocardial injury with necrosis but there is significant overlap with what might be 
regarded as type 2 MI. In patients with traumatic myocardial injury such as a penetrating 
chest wound involving the heart or a road traffic accident when the patient is young troponin 
elevation is clearly non-ischaemic. In the patient on the intensive care unit with hypotension 
and probable underlying myocardial ischaemia the distinction is rather more difficult. In 
patients with myocarditis imaging clearly shows diffuse myocardial involvement but it is 
impossible to exclude microvascular injury as part of the pathophysiology[47]. In patients 
with rheumatological conditions vascular injury in addition to atherosclerosis may be present. 
 
For type 2 MI to be a useful diagnostic label then it should contribute to prognostic 
assessment and have treatment implications. Studies of the prognostic value of the diagnosis 
of type 2 MI have been contradictory, as shown in Table 1, probably dependant on the 
differing criteria used for defining type 2 myocardial infarction and on different study 
populations. In a large study of 3762 consecutive patients of whom 480 had a myocardial 
infarction, type 1 MI was diagnosed in 360 and type 2 MI in 119[40]. The authors used strict 
criteria for type 2 MI. these included anaemia, hypotension and respiratory failure (on the 
supply side) and tachydysrhythmia and hypertension (on the demand side)[35]. They 
demonstrated that the mortality in those with a final diagnosis of type 2 MI was high and 
higher than that than those patients diagnosed with type 1 MI, with a hazard ratio of 2. 
However, the criteria used would equally apply to patients in the intensive care unit where 
such co-morbidities are common and elevation of troponin is both common and 
prognostic[15 48]. A second large registry study analysed 19,763 patients from the 
SWEDEHEART registry with diagnosis of type 2 MI based on local application of the 
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universal definition of myocardial infarction[37]. Arguably the diagnostic classification was 
less rigorous but the numbers were very large and results from angiography were frequently 
available. The incidence of type 2 myocardial infarction was overall 7.1% but varied from 
0.2%% to 13.0 % (10
th
-90
th
 percentiles). Here, the one year mortality was significantly higher 
in those who had type 2 MI (42.4%) than those with type 1 MI. However, after adjustment 
background characteristics, treatments and clustering by treating hospitals the difference in 
one year mortality was attenuated and did not reach statistical significance of the hazard ratio 
1.03[37]. 180 day mortality has similarly been reported as similar between patients with type 
1 MI and type 2 MI although greater than that of patients having no MI and a normal cardiac 
troponin I at baseline[34]. A survey of 2818 patients from the National acute coronary 
syndrome Israel surveys identified only 127 (4.5%) of patients with type 2 MI but this was 
associated with a significantly higher rate of in-hospital (11.8% versus 4.2%) and one year 
mortality (23.9% versus 8.6%) than type I MI[42]. This study excluded patients admitted to 
medical intensive care units no non-cardiac units. There is some consistency between Type 2 
patients however as shown in table 3. Patients with type 2 MI are older[37 40 42], female [34 
37 40 42]usually have a history of pre-existing vascular disease[37 40], heart failure[35 37 
42], stroke[37 40 42] and other comorbidities and have creatinine elevation[37 40]. 
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Table 3  Comparison of comorbid conditions and previous therapy between individual 
studies. A significantly higher incidence in type 2 myocardial infarction 
patients is indicated by Y. N indicates significantly lower incidence. Levels of  
significance are stated in parentheses, ns = not significantly different. Blank 
entries indicate where data was not available. Shaded cells indicate where 
there is consistency across all studies. 
 
 Saaby [40] Sandoval [34] Stein [42] Baron [37] 
Age Y (<0.0001) ns Y (<0.0001) Y (<0.001) 
Female gender Y (0.03) Y (0.01) Y (<0.0001) Y (<0.001) 
Smoking ns  N (<0.0001) N (0.006) 
Hypertension ns ns Y (<0.0001) Y (0.011) 
Diabetes Y(0.005) ns Y (0.003) Y (<0.001) 
Hyperlipidaemia ns N (0.002) ns  
Previous PCI ns  Y (0.03) NS 
Previous CABG ns  Y (0.02) Y (<0.001) 
Previous AMI ns  Y (0.0001) Y (<0.001) 
Previous CHF Y (<0.0001)  Y (<0.0001) Y (<0.001) 
Previous CVA Y (0.03)  Y (0.0002) Y (<0.001) 
ACE 
ns 
  Y (0.009) 
ARB   Y (0.001) 
B blockers ns   Y (0.001) 
Digitalis    Y (0.001) 
Aspirin/Antiplatelet ns   Y (0.001) 
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agents 
Anticoagulants ns   Y (0.001) 
Statins ns   Y (0.001) 
Diuretics    Y (0.001) 
Max troponin N (<0.0001) N (0.007)  N (0.001) 
Creatinine 
elevation 
Y (<0.0001)   Y (0.001) 
CRF  Y (<0.0001)   
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When it comes to treatment there is even less evidence. There are no recommendations in 
current guidelines or standardised protocols of type 2 MI. Comparison of series reveals that 
patients with type 2 MI receive less invasive assessment in the form of angiography and 
receive less of the accepted secondary prevention treatments normally associated with type I 
[34 36 37 40 42]. Arguably, the optimal treatment will be dependent on the underlying cause 
of the supply-demand mismatch. 
 
Type 2 MI could therefore be considered not to be useful term as it is currently defined. It 
might be more appropriate to consider it as secondary myocardial injury which occurs in 
association with a particular clinical condition and whether it occurs in a patient with or 
without coexisting coronary artery disease. Whether ischaemic related injury can be 
realistically distinguished from non-ischaemic cardiac injury or not is a matter of debate. In a 
large international prospective cohort study f myocardial injury after non-cardiac surgery 
15065 patients were enrolled. 1200 patients had an elevated troponin but only 58.2% would 
have been classified as type 1 AMI and only 15.8% had ischaemic symptoms. An elevated 
troponin after non-cardiac surgery independently predicted 30 day mortality irrespective of 
the presence of an ischaemic feature[49]. 
When assessing patients presenting with suspected acute coronary syndromes that have 
troponin measured it is important to consider the totality of the clinical features and 
investigations. An example of this approach is illustrated in figure 1.  
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Figure 1 Holistic assessment of patients with suspected myocardial injury. 
 
 
This review should be conducted not in a linear way but as a circular review process. Each of 
the three factors in the diagnostic triad, the clinical features, the electrocardiogram and 
troponin values are considered in relation to each other. It is the relative weight of each 
feature that contributes to the final diagnosis. Hence, the electrocardiogram (ECG) is 
considered in relation to the clinical features and troponin. For example, if the ECG shows 
non-specific changes with atypical clinical features and a significantly very elevated troponin, 
the clinical picture is unlikely to be acute myocardial infarction and more likely to be 
myocarditis. Similarly, the troponin values should be considered in relation to the clinical 
features and electrocardiogram. This is particularly where delta values are useful in 
distinguishing between an acute and chronic cause of myocardial injury. Similarly, the 
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clinical features must be considered in relation to the ECG and troponin. A history of acute 
chest trauma even with ECG changes is compatible with acute myocardial injury which is 
non-ischaemic in origin. The diagnosis must take into account the relative contribution of 
each of the diagnostic triad. Examples of the types of factors to be considered are shown 
below. 
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Clinical history 
• Sudden typical ischemic chest pain – favors type 1 AMI 
• Triggering factor causing increased oxygen demand or decreased supply – favors 
secondary myocardial injury (type 2 AMI) 
• Symptoms and signs indicating “non-AMI”, e.g. myocarditis, pulmonary embolism) – 
favors secondary injury or non-ischemic myocardial injury 
Cardiac Troponin 
• High levels – favors type 1 AMI 
• No elevation – excludes myocardial injury 
• No delta changes – favors chronic myocardial injury 
ECG 
• ST-elevation – favors type 1 AMI 
• ST-depression – favors ischemic injury; type 1 or secondary myocardial injury (type 2 
AMI) UA if no cTn elevation. 
• New Q-waves – favors type 1 AMI 
• Rhythm disturbance - favours secondary myocardial injury (type 2 AMI) 
Coronary angiography 
• Culprit lesion with thrombus – favors type 1 AMI 
• Significant CAD without clear culprit lesion – favors secondary myocardial injury 
(type 2 AMI). 
• No significant CAD – favors secondary myocardial injury (type 2 AMI) or non-
ischemic myocardial injury 
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In conclusion, we feel that the term type 2 myocardial infarction should be abandoned and 
replaced with secondary myocardial injury, possibly subdivided into acute and chronic. 
Whether this should include pathophysiology where there is a clear non-ischaemic aetiology 
can be debated but given the considerable overlap between ischaemic and non-ischaemic 
aetiology, it is probably not clinically useful. 
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